Saturday, 7 February 2009


An interesting comment from a senior exec at Pfizer, the (very big) drug company.
They are selling a number of experimental treatments to competitors - these are drugs they have been working on for various conditions ... but they have now taken a strategic direction to focus on cancer, brain disorders and pain relief. Drugs for obesity (and other afflictions) are surplus to requirements.

There is a lesson for the smaller guys in here ... work out what you do well and what you should be doing ... then ditch all the extra stuff that doesn't fit in those two compartments.

No comments: